Differences in time to patient access to innovative cancer medicines in six European countries

Author:

Vancoppenolle Julie M.123ORCID,Franzen Nora123,Koole Simone N.1,Retèl Valesca P.14,van Harten Wim H.1235

Affiliation:

1. Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute‐Antoni van Leeuwenhoek Amsterdam The Netherlands

2. Department Health Technology and Services Research Technical Medical Centre University of Twente Enschede The Netherlands

3. The European Fair Pricing Network Amsterdam The Netherlands

4. Erasmus School of Health Policy & Management Health Technology Assessment (HTA) Erasmus University Rotterdam The Netherlands

5. Organization of European Cancer Institutes (OECI) Brussels Belgium

Abstract

AbstractPatients across Europe face inequity regarding access to anticancer medicines. While access is typically evaluated through reimbursement status or sales data, patients can receive first access through early access programs (EAPs) or off‐label use. This study aims to assess the time to patient access at the hospital level, considering different indications and countries. (Pre‐)registered access to six innovative medicines (Olaparib, Niraparib, Ipilimumab, Osimeritinib, Nivolumab and Ibritunib) was measured using a cross‐sectional survey. First patient access to medicines and indications were collected using the hospital databases. Nineteen hospitals from Hungary, Italy, the Netherlands, Belgium, Switzerland and France participated. Analysis showed that some hospitals achieved patient access before national reimbursement, primarily through EAPs. The average time from EMA‐approval to patient access for these medicines was 2.1 years (Range: −0.9‐7.1 years). Hospitals in Italy and France had faster access compared to Hungary and Belgium. Variation was also found within countries, with specialized hospitals (x̄: −0.9 years; SD: 2.0) more likely to provide patient access prior to national reimbursement than general hospitals (x̄: 0.4 years; SD: 2.9). Contextual differences were observed, with EAPs or off‐label use being more prevalent in Switzerland than Hungary. Recent EMA‐approved indications and drug combinations reached patients at a later stage. Substantial variation in patient access time was observed between and within countries. Improving pricing and reimbursement timelines, fostering collaboration between national health authorities and market authorization holders, and implementing nationally harmonized, data‐generating EAPs can enhance timely and equitable patient access to innovative cancer treatments in Europe.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference46 articles.

1. IQVIA.Global oncology trends 2017: advances complexity and cost.2017.

2. IQVIA.EFPIA Patients W.A.I.T.: Indicator 2021 Survey.2022.

3. Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3